PharmaPrint Stock Sale
- Share via
IRVINE — PharmaPrint Inc. plans to sell 2.25 million shares of common stock to the public, according to a registration statement filed Wednesday with the Securities and Exchange Commission.
The price will be determined by the stock’s trading price at the time the shares are offered, the company said.
PharmaPrint develops pharmaceutical-grade dietary supplements and pharmaceuticals from botanical sources.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
